Additionally, TIM3 is also upregulated on Tregs and leukemic stem cells/MDS blasts, further supporting the potential therapeutic utility of TIM3 inhibitors in MDS [64,65,66]. The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.